Literature DB >> 12116529

Local injection of botulinum toxin type A for hemifacial spasm.

Hirofumi Oyama1, Akira Ikeda, Shigeo Inoue, Yasuhiro Nakashima, Masato Shibuya.   

Abstract

The preliminary experience of botulinum toxin treatment for hemifacial spasm is reported in this study. Five patients were treated with 10 injections of botulinum toxin in total. Botulinum toxin had a good to excellent effect in all cases. Improvement was observed 2 weeks to 1 month after the injection. The duration of improvement was 0-9 months (mean 4.2 months). The peak rank tended to decrease and the duration of improvement increased after several treatments. Hemifacial spasm caused by the anterior inferior cerebellar artery tended to subside easily. In contrast, compression by the vertebral artery was more refractory. Continuous facial spasm caused by operative trauma subsided after the injection, but paroxysmal spasm still occurred when eating or laughing. Spasm caused by trauma disappeared 4.5 months after the injection. The complications, which were facial nerve paresis in two cases (3 injections, 30%) and diplopia in one case (1 injection, 10%), were transient and subsided in 2 weeks.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116529     DOI: 10.2176/nmc.42.245

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  2 in total

1.  Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study.

Authors:  V Maneksha; Sabyasachi Chakrabarty; Meghana Tanwar; Madhavi Ramanatha Pillai
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

Review 2.  Tenth case of bilateral hemifacial spasm treated by microvascular decompression: Review of the pathophysiology.

Authors:  Warley Carvalho da Silva Martins; Lucas Alverne Freitas de Albuquerque; Gervásio Teles Cardoso de Carvalho; Jules Carlos Dourado; Marcos Dellaretti; Atos Alves de Sousa
Journal:  Surg Neurol Int       Date:  2017-09-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.